Factors related to the mortality risk of severe hand, foot, and mouth ... - BMC Infectious Diseases
Huang CC, Liu CC, Chang YC, Yeh TF, et al. Neurologic complications in children with enterovirus 71 infection. N Engl J Med. 1999;341(13):936–42. https://doi.org/10.1056/NEJM199909233411302.
Xie YH, Chongsuvivatwong V, Tang Z, et al. Spatio-temporal clustering of hand, foot, and mouth disease at the county level in Guangxi, China. PLoS ONE. 2014;9(2):e88065. https://doi.org/10.1371/journal.pone.0088065.
Chen M, Ju Y, Chen M, et al. Epidemiological and genetic characteristics of EV71 in hand, foot, and mouth disease in Guangxi, southern China, from 2010 to 2015. PLoS ONE. 2017;12(12):e0188640. https://doi.org/10.1371/journal.pone.0188640.
Chang LY, Lin HY, Gau SS, et al. Enterovirus A71 neurologic complications and long-term sequelae. J Biomed Sci. 2019;26(1):57. https://doi.org/10.1186/s12929-019-0552-7.
Li YP, Liang ZL, Gao Q, et al. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, phase I clinical trial. Vaccine. 2012;30(22):3295–303. https://doi.org/10.1016/j.vaccine.2012.03.010.
Li YP, Liang ZL, Xia JL, et al. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial. J Infect Dis. 2014;209(1):46–55. https://doi.org/10.1093/infdis/jit429.
Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–28. https://doi.org/10.1056/NEJMoa1304923.
Li R, Liu L, Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829–37. https://doi.org/10.1056/NEJMoa1303224.
Li JX, Song YF, Wang L, et al. Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert Rev Vaccines. 2016;15(1):129–37. https://doi.org/10.1586/14760584.2016.1096782.
Wang J, Jiang L, Zhang C, He W, Tan Y, Ning C. The changes in the epidemiology of hand, foot, and mouth disease after the introduction of the EV-A71 vaccine. Vaccine. 2021;39(25):3319–23. https://doi.org/10.1016/j.vaccine.2021.05.009.
Ministry of Health of the People's Republic of China. Guide of diagnosis and Treatment for Hand, Foot, Mouth disease (2010 version). http://yzs.satcm.gov.cn/gongzuodongtai/2018-03-24/3073.html.
Xing W, Liao Q, Viboud C, et al. Hand, foot, and mouth disease in China, 2008–12: an epidemiological study. Lancet Infect Dis. 2014;14(4):308–18. https://doi.org/10.1016/S1473-3099(13)70342-6.
The Ministry of Health of China. Guidelines for the Prevention and Control of Hand, Foot, and Mouth disease (2009 version). http://www.gov.cn/gzdt/2009-06/04/content_1332078.htm.
The Ministry of Health of China. Guidelines for the Prevention and Control of Hand, Foot, and Mouth disease (2008 version).http://www.gov.cn/yjgl/2008-05/03/content_960347.htm.
Peng D, Ma Y, Liu Y, Lv Q, Yin F. Epidemiological and aetiological characteristics of hand, foot, and mouth disease in Sichuan Province, China, 2011–2017. Sci Rep. 2020;10(1):6117. https://doi.org/10.1038/s41598-020-63274-3.
Sun Z, Zhang G, Guo P, et al. Epidemiological characterizations, pathogen spectrum and molecular characteristics of Coxsackievirus A16 from patients with HFMD in Yantai, Shandong, China between 2011 and 2015. Hum Vaccin Immunother. 2017;13(8):1831–8. https://doi.org/10.1080/21645515.2017.1318233.
Huang J, Liao Q, Ooi MH, et al. Epidemiology of recurrent hand, foot and mouth disease, China, 2008–2015. Emerg Infect Dis. 2018;24(3):432–42. https://doi.org/10.3201/eid2403.171303.
Moosazadeh M, Abedi G, Afshari M, Kheradmand E, et al. Prevalence of enterobius vermicularis among children in Iran: a systematic review and meta-analysis. Osong Public. Health Res Perspect. 2017;8(2):108–15.
Jiang FC, Yang F, Chen L, et al. Meteorological factors affect the hand, foot, and mouth disease epidemic in Qingdao, China, 2007–2014. Epidemiol Infect. 2016;144(11):2354–62. https://doi.org/10.1017/S0950268816000601.
Jiang L, Wang J, Zhang C, et al. Effectiveness of enterovirus A71 vaccine in severe hand, foot, and mouth disease cases in Guangxi, China. Vaccine. 2020;38(7):1804–9. https://doi.org/10.1016/j.vaccine.2019.12.025.
Zhu J, Shi P, Zhou W, et al. Assessment of temperature-hand, foot, and mouth disease association and its variability across urban and rural populations in Wuxi, China: a distributed lag nonlinear analysis. Am J Trop Med Hyg. 2020;103(5):2091–9. https://doi.org/10.4269/ajtmh.20-0329.
Wang J, Hu T, Sun D, et al. Epidemiological characteristics of hand, foot, and mouth disease in Shandong, China, 2009–2016. Sci Rep. 2017;7(1):8900. https://doi.org/10.1038/s41598-017-09196-z.
Ji H, Fan H, Ai J, et al. Neurocognitive deficits and sequelae following severe hand, foot, and mouth disease from 2009 to 2017, in JiangSu Province, China: a long-term follow-up study. Int J Infect Dis. 2022;115:245–55. https://doi.org/10.1016/j.ijid.2021.11.026.
Liu H, Song G, He N, et al. Spatial-temporal variation and risk factor analysis of hand, foot, and mouth disease in children under 5 years old in Guangxi, China. BMC Public Health. 2019;19(1):1491. https://doi.org/10.1186/s12889-019-7619-y.
Xu C, Zhang X, Xiao G. Spatiotemporal decomposition and risk determinants of hand, foot and mouth disease in Henan. China Sci Total Environ. 2019;657:509–16. https://doi.org/10.1016/j.scitotenv.2018.12.039.
Sun BJ, Chen HJ, Chen Y, et al. The risk factors of acquiring severe hand, foot, and mouth disease: a meta-analysis. Can J Infect Dis Med Microbiol. 2018;2018:2751457. https://doi.org/10.1155/2018/2751457.
Qiu J, Lu XL, Liu X, et al. Derivation and validation of a mortality risk score for severe hand, foot and mouth disease in China. Sci Rep. 2017;7(1):3371. https://doi.org/10.1155/2018/2751457.
Tao J, He XY, Shi Y, et al. Epidemiology of 45,616 suspect cases of hand, foot and mouth disease in Chongqing, China, 2011–2015. Sci Rep. 2017;7:45630. https://doi.org/10.1038/srep45630.
Li Y, Zhou YH, Cheng YB, et al. Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017–18: a test-negative case-control study. Lancet Child Adolesc Health. 2019;3(10):697–704. https://doi.org/10.1016/S2352-4642(19)30185-3.
Wang XL, An ZJ, Huo D, et al. Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing. China Hum Vaccin Immunother. 2019;15(5):1183–90. https://doi.org/10.1080/21645515.2019.1581539.
Du ZC, Huang Y, Bloom MS, et al. Assessing the vaccine effectiveness for hand, foot, and mouth disease in Guangzhou, China: a time-series analysis. Hum Vaccin Immunother. 2021;17(1):217–23. https://doi.org/10.1080/21645515.2020.1763076.
Wang W, Song J, Wang J, et al. Cost-effectiveness of a national enterovirus 71 vaccination program in China. PLoS Negl Trop Dis. 2017;11(9):e0005899. https://doi.org/10.1371/journal.pntd.0005899.
Jiang HC, Zhang Z, Rao Q, et al. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China. Emerg Microbes Infect. 2021;10(1):619–28. https://doi.org/10.1080/22221751.2021.1899772.
RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. https://doi.org/10.1056/NEJMoa2021436.
Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184(2):476–88. https://doi.org/10.1016/j.cell.2020.12.015.
Wang L, He W, Yu X, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020;80(6):639–45. https://doi.org/10.1016/j.jinf.2020.03.019.
Comments
Post a Comment